



Developing Medicines through Collaboration

Professor Malcolm Skingle CBE DSc PhD Director – Academic Liaison

Drug Discovery

25th September 2013 University of Birmingham

Science Capital's "Innovative Healthcare: from Mechanisms to Medicine" meeting



Changing face of Innovation

The Past....Large Corporate R&D facilities Secretive smart scientists, low level of collaboration Closed Innovation

 The Present....leaner business units Increased levels of collaboration More outsourcing, more partnerships
Open Innovation



Open Innovation



The Innovation Ecosystem



R&D leverages internal and external engines

41 Discovery Performance Units



50 External innovation engines



External innovation engines are defined as: Partnerships of greater than £10m in value but focused on assets that are currently Pre-POC. List includes: In-licenses, option collaborations, technology deals which enable producing new molecules, and academic collaborations ultimately focused on producing new molecules



The Structural Genomics Consortium an Open Access Public Private Partnership est. 2004



The Structural Genomics Consortium - an open access public-private partnership

Mandate to place protein structures of relevance to human health into the public domain, free from restrictions on use.

Funders nominate the SGC Target List of proteins

Phase 1: (2005-07)

Year 1 50 protein structures Year 2 100 structures Year 3 200 structures



Protein Kinases (Catalytic Domains)

Human kinases (518 in genome)





The Structural Genomics Consortium - an open access public-private partnership

• Phase 1: (2005-07)

455 protein structures solved

• Phase 2: (2007-11)

Target of 660 structures from the Target List (2400 proteins) plus 8 human integral membrane proteins

SGC releases 1000th protein structure.

Wednesday, September 28, 2011 an international public-private partnership publishes 1000th structure JmjD2C

- Operations started in June 2004
- A model of open access research
- 200-strong team (Oxford + Toronto)
- >\$250M investment attracted so far
- Open Access Policy:





SGC Scientific Programs

Structural genomics

Focus on protein families of relevance to drug discovery (soluble and membrane) Human proteins and proteins from human parasites

Chemical biology

Development of chemical probes to explore protein function and enable target validation Focus on epigenetics (readers, writers and erasers)

Antibody generation

Utilize trove of purified proteins as antigens for generation of recombinant antibodies using phage display technologies Partnership with LifeTechnologies/Invitrogen

www.thesgc.org

Developing Chemical Probes for Epigenetics



*

Only GSK scientists can view data with compound structures e.g. Potency <100nM, Selectivity

JlaxoSmith

>100, Cellular activity <1uM

OPEN ACCESS SCIENCE IS DELIVERING GLOBAL IMPACT

11 new chemical probes in the last 30 months

250+ Collaborations globally (>20 countries)

~1.4 peer-reviewed publications/week (470+)

20% of the yearly global output (novel human structures: now >1450)

2200+ purified human proteins

www.thesgc.org

SGC Key Features

- Lead by an intermediary organisation
 Not for profit company
- Strong management industrial style project driven
- Brand building
- Multi-stream funded
- Research outputs placed in public domain



We are looking for

innovation wherever

it may originate 🕨

